Composition, form of production and packaging
? Capsules are solid, size в„–00, transparent, dark green color; the contents of the capsules are a light yellow powder.
GraminexВ® G60 (water-soluble fraction of microbiologically fermented extract of plant pollen) 120 mg
GraminexВ® GFX (fat-soluble fraction of a microbiologically fermented extract of plant pollens) 6 mg
Excipients: microcrystalline cellulose - 266 mg, silicon dioxide colloid - 7.6 mg, maltodextrin 10DE - 176.2 mg, calcium stearate - 16 mg, calcium dihydrogen phosphate - 3.2 mg.
The composition of the capsule shell: chlorophyllin-copper sodium - 0.83 mg, hypromellose - 117.17 mg.
50 pcs. - bottles of dark glass (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2015.
A preparation of vegetable origin used for prostate diseases. Cernilton В® forte has an anti-inflammatory and anti-edematic effect, promotes the regulation of metabolic processes.
One of the pharmacological properties of the drug Cernilton В® forte is a dose-dependent inhibition of COX and 5-lipoxygenase, which leads to inhibition of the synthesis of mediators of inflammation of the arachidonic acid cycle - prostaglandins and leukotrienes - and, consequently, to a decrease in inflammation and edema of the prostate tissue. The drug helps to eliminate the pain syndrome.
Cernilton В® forte has a muscle relaxant effect, which leads to a relaxation of the smooth muscle elements of the posterior wall of the urethra and an improvement in urination.
The drug reduces the volume of the prostate gland due to inhibition of 5? -reductase, selectively blocks? 1- adrenoreceptors of smooth muscle elements of the urethra, has an antiandrogenic effect. Promotes the improvement of erectile function.
As part of complex therapy:
- acute and chronic prostatitis;
- benign prostatic hyperplasia;
- benign prostatic hyperplasia in combination with prostatitis.
The drug is administered orally 30 minutes before meals, with a small amount of water.
In acute prostatitis appoint 2 caps. 3 times / day. The duration of treatment is determined by the attending physician and is, on average, 3 months.
In chronic prostatitis appoint 1 caps. 3 times / day. The duration of treatment is determined individually by the attending physician and is, on average, 3-6 months.
With benign prostatic hyperplasia, one capsule is prescribed. 3 times / day. The duration of treatment is determined individually by the attending physician and is, on average, from 6 to 12 weeks, but can be increased to 6 months.
With increased individual sensitivity to the components of the drug, allergic reactions are possible.
- Hypersensitivity to the components of the drug.
To date, cases of an overdose of the drug Cernilton В® forte have not been observed.
There is no information on the interaction of the drug Cernilton В® forte with other drugs.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored in a dry, protected from light, out of reach of children at a temperature of no higher than 25 В° C. Shelf life - 5 years. Do not use after the expiration date.